Skip to main content
Premium Trial:

Request an Annual Quote

Signal Genetics Reports 18 Percent Increase in Q2 Revenues

NEW YORK (GenomeWeb) – Cancer diagnostics firm Signal Genetics on Thursday reported an 18 percent year-over-year increase in its second quarter revenues.

In a form 10-Q filed with the US Securities and Exchange Comission, the New York-based company, which went public in June, said that it had revenues of $1.3 million for the three months ended June 30,, compared to $1.1 million in the year-ago quarter.

It also said that it raised net proceeds of about $6.1 million from its IPO.

Its net loss for the second quarter was $3.3 million, or $1.13 per share, compared to a net loss of $539,691, or $.24 per share, a year ago.

The company slashed its R&D spending to $9,023 from $22,820 a year ago, while its SG&A costs were trimmed 2 percent to $525,465 from $537,403. Signal Genetics said that the decrease in R&D costs resulted from the abandonment of certain research projects that were deemed unviable.

The company finished the quarter with $7.7 million in cash and cash equivalents.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.